Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fentanyl. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 9/20 | 0.80 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.80 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.80 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.80 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.80 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.80 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.80 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.80 |
| ▸ | DRD2 | P14416 | 1/20 | 0.80 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.80 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.80 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.80 |
| ▸ | MAOA | P21397 | 1/20 | 0.80 |
| ▸ | DRD4 | P21917 | 1/20 | 0.80 |
| ▸ | MAOB | P27338 | 1/20 | 0.80 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.80 |
| ▸ | HRH1 | P35367 | 1/20 | 0.80 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.80 |
| ▸ | DRD3 | P35462 | 1/20 | 0.80 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fentanyl SCHEMBL216836 | 1.00 | OPRM1 (0.80) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 | |
| Fentanyl SCHEMBL40733 | 1.00 | OPRM1 (0.80) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 | |
| Fentanyl SCHEMBL6002326 | 1.00 | OPRM1 (0.80) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 | |
| Fentanyl SCHEMBL6908995 | 1.00 | OPRM1 (0.80) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 | |
| Fentanyl SCHEMBL27481710 | 0.99 | OPRM1 (0.78) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 | |
| Fentanyl SCHEMBL19066928 | 0.99 | OPRM1 (0.78) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 | |
| Fentanyl SCHEMBL2722646 | 0.96 | OPRM1 (0.74) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 | |
| Fentanyl SCHEMBL1773864 | 0.91 | OPRM1 (0.66) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 | |
| Fentanyl SCHEMBL8804 | 0.89 | OPRM1 (1.00) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 | |
| Fentanyl SCHEMBL916599 | 0.89 | OPRM1 (1.00) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9427435-B2 | Narcotic emulsion formulations for treatment of cancer pain | TEIKOKU PHARMA USA, INC. (US) | 2016-08-30 | — | — | US | claimed |
| US-20150141461-A1 | Narcotic Emulsion Formulations for Treatment of Cancer Pain | TEIKOKU PHARMA USA, INC. | 2015-05-21 | — | — | US | claimed |
| EP-2400838-A1 | NARCOTIC EMULSION FORMULATIONS FOR TREATMENT OF CANCER PAIN | Teikoku Pharma USA, Inc. (US) | 2012-01-04 | — | — | EP | claimed |
| EP-2276440-A2 | NARCOTIC EMULSION FORMULATIONS FOR TREATMENT OF SURGICAL PAIN | Teikoku Pharma USA, Inc. (US) | 2011-01-26 | — | — | EP | claimed |
| WO-2010098897-A1 | NARCOTIC EMULSION FORMULATIONS FOR TREATMENT OF CANCER PAIN | TEIKOKU PHARMA USA, INC. (US) | 2010-09-02 | — | — | WO | claimed |
| US-20100216842-A1 | Narcotic Emulsion Formulations for Treatment of Cancer Pain | TEIKOKU PHARMA USA INC. | 2010-08-26 | — | — | US | claimed |
| WO-2009140059-A2 | NARCOTIC EMULSION FORMULATIONS FOR TREATMENT OF SURGICAL PAIN | TEIKOKU PHARMA USA, INC. (US) | 2009-11-19 | — | — | WO | claimed |
| US-20090286832-A1 | NARCOTIC EMULSION FORMULATIONS FOR TREATMENT OF SURGICAL PAIN | TEIKOKU PHARMA USA INC. | 2009-11-19 | — | — | US | claimed |
| US-9427435-B2 | Narcotic emulsion formulations for treatment of cancer pain | TEIKOKU PHARMA USA, INC. (US) | 2016-08-30 | — | — | US | disclosed |
| EP-2400838-B1 | NARCOTIC EMULSION FORMULATIONS FOR TREATMENT OF CANCER PAIN | TEIKOKU PHARMA USA INC (US) | 2016-05-11 | — | — | EP | disclosed |
| US-20150141461-A1 | Narcotic Emulsion Formulations for Treatment of Cancer Pain | TEIKOKU PHARMA USA, INC. | 2015-05-21 | — | — | US | disclosed |
| US-8871791-B2 | Narcotic emulsion formulations for treatment of cancer pain | TEIKOKU PHARMA USA, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20140296830-A1 | METHODS OF ADMINISTERING DRUGS IN AN IMPLANTABLE MULTI-CHAMBER PUMP | Jazz Pharmaceuticals, Inc. (US) | 2014-10-02 | — | — | US | disclosed |
| EP-2400838-A1 | NARCOTIC EMULSION FORMULATIONS FOR TREATMENT OF CANCER PAIN | Teikoku Pharma USA, Inc. (US) | 2012-01-04 | — | — | EP | disclosed |
| EP-1641441-A2 | TAMPER-RESISTANT TRANSDERMAL DOSAGE FORM COMPRISING AN ACTIVE AGENT COMPONENT AND AN ADVERSE AGENT COMPONENT AT THE DISTAL SITE OF THE ACTIVE AGENT LAYER | Purdue Pharma Ltd. (US) | 2006-04-05 | — | — | EP | disclosed |
| EP-1638535-A1 | SUBCUTANEOUS IMPLANTS HAVING LIMITED INITIAL RELEASE OF THE ACTIVE PRINCIPLE AND SUBSEQUENT LINEARLY VARYING EXTENDED RELEASE THEREOF | Mediolanum Pharmaceuticals Limited (IE) | 2006-03-29 | — | — | EP | disclosed |
| WO-2005000278-A1 | SUBCUTANEOUS IMPLANTS HAVING LIMITED INITIAL RELEASE OF THE ACTIVE PRINCIPLE AND SUBSEQUENT LINEARLY VARYING EXTENDED RELEASE THEREOF | MEDIOLANUM PHARMACEUTICALS LTD. (IE) | 2005-01-06 | — | — | WO | disclosed |
| WO-2004098567-A2 | TAMPER-RESISTANT TRANSDERMAL DOSAGE FORM COMPRISING AN ACTIVE AGENT COMPONENT AND AN ADVERSE AGENT COMPONENT AT THE DISTAL SITE OF THE ACTIVE AGENT LAYER | PURDUE PHARMA L.P. (US) | 2004-11-18 | — | — | WO | disclosed |
| US-5716631-A | SOLUBILIZED WITHIN POLYMER MATRIX | RDN THERAPEUTICS INC. (CA) | 1998-02-10 | — | — | US | disclosed |
| US-5709883-A | SOLUBILIZED IN POLYMER MATRIX BLEND; SUSTAINED RELEASE | L.A.M. PHARMACEUTICALS, LLC (US) | 1998-01-20 | — | — | US | disclosed |